RE:RE:(TSXV:BTI.V; OTCQB:BIOAF): Ph2 Ready Rare Orphan Assets
"Unexpected", and we have to pay for the development, how dilutively is my concern?
Has anyone worked out how dilutive the Lind deal, if that $7m remaining is used, is likely to be?
I find it difficult to get a handle on all the "extras" that will also eventually (adding the interest) turn into shares. Then there is an unknown conversion price of course, but just knowing how much debt the loan could turn into would be useful.
And I'm wondering how easy will it be for Lind to end up having enough shares to control the company.
Yer, I know, I should be excited by Bioasis being nearer to the clinical trials, but I just wasn't expecting it to be the result of an acquisition that will need funding.
MD